(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/219042 A1

(51) International Patent Classification:
G16H 50/20 (2018.01) *G16H 50/50* (2018.01)
G16H 50/70 (2018.01)

(21) International Application Number:
PCT/EP2022/059871

(22) International Filing Date:
13 April 2022 (13.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21168362.8 14 April 2021 (14.04.2021) EP

(71) Applicant *(for all designated States except DE, US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for DE only)*: **ROCHE DIABETES CARE GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) Applicant *(for US only)*: **ROCHE DIABETES CARE, INC.** [US/US]; 9115 Hague Road, Indianapolis, Indiana 46250 (US).

(72) Inventors: **ADELBERGER, Daniel**; c/o Universität Linz, Altenberger Strasse 69, 4040 Linz (AT). **DEL RE, Luigi**; c/o Universität Linz, Altenberger Strasse 69, 4040 Linz (AT). **REITERER, Florian**; c/o Universität Linz, Altenberger Strasse 69, 4040 Linz (AT). **RINGEMANN, Christian**; c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim (DE). **SCHRANGL, Patrick**; c/o Universität Linz, Altenberger Strasse 69, 4040 Linz (AT).

(74) Agent: **VON CAMPENHAUSEN, Dr. Harald**; Roche Diabetes Care GmbH, Patent Department, Sandhofer Strasse 116, 68305 Mannheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHOD AND MEANS FOR POSTPRANDIAL BLOOD GLUCOSE LEVEL PREDICTION




FIG. 1

(57) Abstract: Method and means for postprandial blood glucose level prediction The invention relates to a method (100) for predicting blood glucose levels, in particular for postprandial blood glucose level prediction, the method being computer-implemented and comprising: receiving (101) a first medical data set of a patient covering a time range, said first medical data set comprising glucose data and further other medical data of said patient, extracting (102) a second medical data set from said first medical data set, wherein the second medical data set is a subset of the first medical data set and wherein the extracting comprises at least one of: identifying (103) duplicates in the first medical data set and removing identified duplicates, identifying (104) data values that lie above a predefined maximum threshold data value or identifying (105) data values that lie below a predefined minimum threshold data value and removing data associated to said identified data values, identifying (106) data values that differ from predetermined expected data values by more than a predetermined amount and removing data associated to said identified data values, identifying (107) incomplete data for which data values are missing and removing identified incomplete data, identifying (108) at least one predetermined time-dependent data pattern and removing data associated to said identified time-dependent data pattern, providing (109) the extracted second medical data set as input to a blood glucose level prediction model, and predicting (110) future blood glucose levels of the patient using the output of the blood glucose level prediction model based on the second medical data set.

[Continued on next page]

WO 2022/219042 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*